DelveInsight’s “Alcohol Use Disorder – Market Insights, Epidemiology, and Market Forecast – 2036“ report offers an in-depth understanding of AUD, historical and forecasted epidemiology, as well as the market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
Discover comprehensive forecasts, emerging treatment trends, and competitive intelligence shaping the future of the Alcohol Use Disorder market
Alcohol Use Disorder, or alcoholism, is a condition where excessive drinking affects physical health, thinking, and behavior, characterized by loss of control over alcohol use, inability to quit, cravings, increased tolerance, withdrawal symptoms, and neglect of responsibilities. AUD is linked to serious health, social, and behavioral issues, including liver and heart disease, mental health disorders, accidents, and risky behaviors, arising from a combination of genetic susceptibility and environmental factors such as social influences, stress, and lack of support.
Key Takeaways from the Alcohol Use Disorder Market Report
- According to a September 2025 SEC filing, Adial Pharmaceuticals plans to initiate a Phase III study of AD04 in the first half of 2026, with a potential commercial launch anticipated by 2027 or 2028 via the 505(B)(2) regulatory pathway.
- According to a June 2025 news release, a UCLA clinical trial found that ibudilast did not significantly reduce alcohol consumption compared to placebo overall, though it demonstrated a positive effect among female participants.
- Eli Lilly has introduced brenipatide (LY3537031), a dual GIP/GLP-1 receptor agonist, for AUD, opioid dependence, and asthma, marking a strategic move beyond obesity treatment, currently in Phase III clinical trials.
- Currently approved AUD therapies include CAMPRAL (acamprosate), ANTABUSE (disulfiram), REVIA (oral naltrexone), and VIVITROL (extended-release injectable naltrexone), with generic versions widely available for all except VIVITROL.
- According to DelveInsight’s analysis, the AUD market size in the 7MM was valued at approximately USD 1,100 million in 2025 and is projected to reach approximately USD 3,600 million by 2036, growing at a CAGR of 12.1% during the study period.
- Among all therapies in the US, VIVITROL (naltrexone) holds the highest AUD drugs market share in 2025, while by 2036, AD04 is projected to capture the largest market share.
- The United States has a substantial burden of AUD, with recent estimates suggesting approximately 25 million Americans are affected, and there were 25,648,000 12-month diagnosed prevalent cases of AUD in the US in 2025, projected to decrease by 2036.
- The 12-month diagnosed prevalence of AUD in the United States has shown a modest decline in recent years, decreasing from approximately 10.6% in 2021 to approximately 9.7% in 2025, aligning with reductions in heavy and binge drinking rates, particularly among young adults.
- Nearly 14 million individuals experience moderate to severe AUD disease, and AUD remains largely untreated, with nearly 90% of patients not achieving sustained abstinence under existing therapeutic options.
- AUD affects approximately 70% of males and 30% of females in the EU4 and the UK, with projections indicating a decrease in gender-specific diagnosed prevalence during the forecast period (2026–2036).
- Key AUD Companies: Alkermes, Adial Pharmaceuticals, Eli Lilly and Company, MediciNova, Imbrium Therapeutics (subsidiary of Purdue Pharma), Tempero Bio, Nxera Pharma, Altimmune, and others.
- Key AUD Therapies: VIVITROL (naltrexone), CAMPRAL (acamprosate), ANTABUSE (disulfiram), REVIA (oral naltrexone), AD04 (ondansetron), Brenipatide (LY3537031), MN-166 (ibudilast), Sunobinop (V117957), and others.
Gain Strategic Insights into the Alcohol Use Disorder Market
- Explore the complete Alcohol Use Disorder Market Outlook.
- Download the latest Alcohol Use Disorder Epidemiology Forecast Report.
- Analyze emerging Alcohol Use Disorder pipeline therapies and late-stage assets.
- Evaluate commercial opportunities across the 7MM.
- Understand evolving treatment algorithms and reimbursement scenarios.
Explore detailed market insights and forecasts @ Alcohol Use Disorder Market Report
Alcohol Use Disorder Epidemiology Insights
The AUD epidemiology section provides insights into the historical and current AUD patient pool and forecasted trends across the seven major markets (7MM): the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan for the study period 2022–2036.
The epidemiology analysis includes:
- 12-month Alcohol Use Disorder Diagnosed Prevalent Cases.
- Alcohol Use Disorder Gender-specific Diagnosed Prevalent Cases.
- Alcohol Use Disorder Age-specific Diagnosed Prevalent Cases.
- Alcohol Use Disorder Severity-specific Diagnosed Prevalent Cases.
- Total Alcohol Use Disorder Treated Cases.
Among EU4 and the UK, Germany accounted for the most cases of AUD, followed by France and least in Spain, in 2025. In 2025, the highest number of AUD cases was in the 45–64 years age group, with 8,977,000 cases in the US.
Request a Sample Report to Explore Alcohol Use Disorder Epidemiology Trends and Forecasts @ Alcohol Use Disorder Epidemiology Forecast Report
Alcohol Use Disorder Treatment Landscape
The AUD treatment landscape has evolved with the availability of approved pharmacological therapies and a growing pipeline focused on precision medicine and novel neurobiological mechanisms.
Current treatment strategies include CAMPRAL (acamprosate), ANTABUSE (disulfiram), REVIA (oral naltrexone), and VIVITROL (extended-release injectable naltrexone), combined with psychosocial interventions and behavioral therapy.
Novel pipeline therapies are increasingly targeting genetically defined patient populations and new biological pathways, including GLP-1 receptor agonists and inflammatory pathway inhibitors.
Marketed Therapies
- VIVITROL (naltrexone): Alkermes – the first and only extended-release medication for alcohol dependence, administered once monthly as an intramuscular injectable opioid antagonist alongside psychosocial support.
- CAMPRAL (acamprosate): Approved therapy used to help maintain abstinence in alcohol-dependent patients.
- ANTABUSE (disulfiram): Approved therapy that discourages alcohol consumption through aversive reactions.
- REVIA (oral naltrexone): Oral opioid antagonist used for relapse prevention in AUD.
Emerging Therapies
- AD04 (ondansetron): Adial Pharmaceuticals – a Phase III oral serotonin-3 (5-HT3) receptor antagonist for genetically defined moderate-to-severe AUD patients, with an anticipated US launch in 2028.
- Brenipatide (LY3537031): Eli Lilly and Company – a Phase III dual GIP/GLP-1 receptor agonist being developed for moderate-to-severe AUD.
- MN-166 (ibudilast): MediciNova – a Phase II oral small molecule targeting PDE4 and inflammatory cytokines.
- Sunobinop (V117957): Imbrium Therapeutics – a Phase II oral NOP receptor agonist for moderate-to-severe AUD.
Learn More About Emerging Alcohol Use Disorder Therapies and Clinical Trial Developments @ Alcohol Use Disorder Clinical Trial Insights
Alcohol Use Disorder Market Drivers
- Rising global alcohol consumption, particularly in emerging economies and younger populations.
- Growing awareness and diagnosis of mental health and substance abuse disorders.
- Advancements in pharmacological treatments, including anti-craving medications and neurobiologically targeted therapies.
- Government initiatives and support programs encouraging treatment adoption.
- High unmet medical needs driving demand for more effective, long-term, and personalized treatment options.
Alcohol Use Disorder Market Barriers
- Limited efficacy of existing behavioral and pharmacological treatments, with nearly 90% of patients not achieving sustained abstinence.
- Limited understanding of the neuropsychological basis and complexity of AUD.
- Lack of predictive tools for treatment response, leading to trial-and-error care.
- Social stigma and lack of awareness contributing to low treatment uptake.
- Significant underpenetration of the US market despite a large patient population, with pharmacotherapy uptake remaining extremely low.
Competitive Landscape and Pipeline Analysis
The competitive landscape of the Alcohol Use Disorder market includes established pharmaceutical companies and emerging biotechnology companies actively developing innovative therapies for alcohol dependence.
The current landscape is anchored by approved therapies including VIVITROL, CAMPRAL, ANTABUSE, and REVIA, while late-stage pipeline candidates such as AD04, Brenipatide, MN-166, and Sunobinop are expected to expand treatment options by addressing significant unmet clinical needs.
Several companies are pursuing precision medicine, GLP-1 receptor agonists, and novel inflammatory pathway inhibitors to improve long-term treatment outcomes.
Discover Which Companies and Therapies Are Expected to Shape the Alcohol Use Disorder Market Through 2036 @ Alcohol Use Disorder Pipeline Insights
Scope of the Alcohol Use Disorder Market Report
- Coverage: 7MM (United States, EU4 [Germany, France, Italy, and Spain], the United Kingdom, and Japan).
- Study Period: 2022–2036.
- Forecast Period: 2026–2036.
- Key Companies: Alkermes, Adial Pharmaceuticals, Eli Lilly and Company, MediciNova, Imbrium Therapeutics, Tempero Bio, Nxera Pharma, Altimmune, and other emerging market players.
- Key Therapies: VIVITROL (naltrexone), CAMPRAL (acamprosate), ANTABUSE (disulfiram), REVIA (oral naltrexone), AD04 (ondansetron), Brenipatide (LY3537031), MN-166 (ibudilast), Sunobinop (V117957), and other emerging therapies.
- Focus Areas: Epidemiology, Market Forecast, Drug Uptake, Emerging Therapies, Market Drivers and Barriers, Reimbursement, and Unmet Needs.
Contact Information
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: info@delveinsight.com
Phone: +1 469 945 7679
Address: 304 S. Jones Blvd #2432, Las Vegas, Nevada 89107, United States
Website: https://www.delveinsight.com
About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides actionable market intelligence and strategic insights across the pharmaceutical, biotechnology, and healthcare industries. With expertise in epidemiology forecasting, competitive intelligence, and pipeline analysis, DelveInsight helps organizations make informed business decisions and stay ahead in an evolving healthcare landscape.
